Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.
Henley, Susie MD;
Wild, Edward J;
Hobbs, Nicola Z;
Frost, Chris;
MacManus, David G;
Barker, Roger A;
Fox, Nick C;
Tabrizi, Sarah J;
(2009)
Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.
Movement disorders, 24 (6).
pp. 932-936.
ISSN 0885-3185
DOI: https://doi.org/10.1002/mds.22485
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole-brain atrophy rates over 1 year in early and premanifest HD subjects, and controls. Early HD subjects had statistically significantly (P = 0.007) increased (threefold higher) rates of whole-brain atrophy compared with controls. Higher atrophy rates were associated with longer CAG repeat length. MRI-based measures of whole-brain atrophy may have potential as a measure of progression in HD.
